GIA announces the release of a global market report on Synthetic Biology. Global Synthetic biology market is projected to exceed $4.5 billion by the year 2015. Synthetic biology is expected to provide major advances in the areas of biomedicine, biopharmaceuticals synthesis, biosecurity, energy and environment, sustainable chemical segment, and biomaterials/smart materials production. Significant investments are expected in the synthetic biology field.

San Jose, CA (Vocus) July 13, 2010 -- Synthetic biology is an emerging technology, which enables the creation of organisms from a genetic code that is not found in the natural world. The new biological research area integrates sciencewith engineering for designing and building novel biological entities, including cells, genetic circuits and enzymes, or for redesigning active biological systems and living organisms, such as bacteria.

Synthetic Biology is gaining tremendous recognition as a transformative technology that not just has the capability to address food shortage and security issues but also tackle other threats such as climate change, water deficit and energy shortages. The market would be driven by growing popularity of synthetic biology in the areas of energy and chemicals, biotechnology and pharmaceuticals, and other potential applications.

Scotland and the UK have made significant strides in the field of synthetic biology, as stated by a new report on Synthetic Biology. However, of late, the market has seen the emergence of several European and Far East countries. Synthetic biology is also gaining popularity in Japan and China. In terms of research, most of the research in synthetic biology is being pioneered by the US groups; however, a few UK universities (including Cambridge and Imperial College) are also engaged in the work. The research community in Europe is relatively slower in embracing the field. Nevertheless, the EU community possesses enormous expertise that can be tapped in order to develop a European synthetic biology programme. Scotland’s £2.5 million worth Genome Segment Assembly (GSA)programme, expected to offer tremendous opportunity to the country for gaining competitive advantage in the synthetic biology market.

Key players analyzed include Amyris Biotechnologies Inc., ATG Biosynthetics GmbH, Blue Heron Biotechnology, Inc., Chromatin Inc., DNA2.0, febit Synbio GmbH, GENEART AG, GenScript USA, Inc., Gevo Inc., LS9 Inc., Solazyme Inc., Sloning BioTechnology GmbH, Synthetic Genomics Inc., Verdezyne Inc.

For more details about this market research report, please visit – http://www.strategyr.com/Synthetic_Biology_Market_Report.asp
From: http://www.earthtimes.org/articles/press/global-industry-analysts-inc,1379787.html